Welcome to our dedicated page for Ligand Pharma news (Ticker: LGND), a resource for investors and traders seeking the latest updates and insights on Ligand Pharma stock.
Ligand Pharmaceuticals Inc. (NASDAQ: LGND) is a biopharmaceutical innovator specializing in drug discovery technologies and strategic licensing partnerships. This page aggregates official updates about the company's research advancements, financial milestones, and Captisol® technology applications.
Investors and industry professionals will find timely updates on earnings reports, regulatory developments, and partnership announcements. Our curated collection includes press releases about new licensing agreements, clinical trial progress, and intellectual property expansions that shape LGND's position in the pharmaceutical sector.
Key areas of coverage include updates on royalty-bearing partnerships, Captisol® formulation breakthroughs, and corporate financial strategies. Bookmark this page to monitor how Ligand's lean operational model and diversified revenue streams continue to drive innovation in drug development.
Ligand Pharmaceuticals (LGND) reported strong financial results for Q4 and full year 2024, with total revenues reaching $167.1 million for the year. The company saw a 28% growth in royalty revenue, driven by strong performance across major commercial programs.
Q4 2024 revenues were $42.8 million, up 52% from Q4 2023, primarily due to royalty revenue of $34.8 million. However, LGND reported a Q4 GAAP net loss of $31.1 million ($1.64 per share), compared to net income of $18.2 million in Q4 2023.
Key highlights include FDA approvals for three portfolio products with blockbuster potential: Verona's Ohtuvayre, Travere's Filspari, and Merck's Capvaxive. The company reiterated its 2025 guidance of $180-$200 million in revenues and adjusted earnings per share of $6.00-$6.25.
Ligand Pharmaceuticals (Nasdaq: LGND) has announced a $75 million royalty financing agreement with Castle Creek Biosciences to support the Phase 3 clinical study of D-Fi (FCX-007), an autologous gene-modified cell therapy for dystrophic epidermolysis bullosa (DEB). Ligand invested $50 million, leading a syndicate of co-investors who contributed $25 million, in exchange for a high-single digit royalty on worldwide sales of D-Fi. The syndicate includes Paragon Biosciences, Valor Equity Partners, and XOMA Royalty (Nasdaq: XOMA).
D-Fi, an injectable therapy, addresses DEB, a rare genetic skin disorder caused by a mutation in the COL7A1 gene. The therapy uses genetically modified dermal fibroblasts to express COL7 protein, aiding the formation of skin anchoring fibrils. Clinical studies have shown D-Fi to be generally well tolerated, with injection site reactions being the primary adverse effects.
D-Fi has received multiple FDA designations, including Orphan Drug, Rare Pediatric Disease, Fast Track, and Regenerative Medicine Advanced Therapy for the treatment of recessive dystrophic epidermolysis bullosa (RDEB).
Ligand Pharmaceuticals (Nasdaq: LGND) has scheduled its fourth quarter and full year 2024 financial results announcement for Thursday, February 27, 2025, before U.S. markets open. The company will host a conference call and webcast at 8:30 a.m. ET (5:30 a.m. PT) on the same day to discuss the results and provide a business update. The call will be accessible via phone for U.S. & Canada (800-715-9871) and International (646-307-1963) participants using conference ID 8755336. A live webcast and replay will also be available.
Ligand Pharmaceuticals (Nasdaq: LGND) has announced its participation in the upcoming Oppenheimer 35th Annual Healthcare Life Sciences Conference. CEO Todd Davis and CFO Tavo Espinoza will deliver a presentation on February 11, 2025, at 2:40 p.m. Eastern Time.
The company's management team will be available for one-on-one meetings with investors and conference attendees. Interested investors can arrange meetings through their Oppenheimer representative.
Ligand Pharmaceuticals (Nasdaq: LGND) announced its 2025 guidance during its Investor and Analyst Day, projecting total revenue of $180-200 million, representing a 17% increase over 2024. The company expects royalty revenue of $135-140 million, Captisol sales of $35-40 million, and contract revenue of $10-20 million, with core adjusted earnings per diluted share of $6.00-6.25.
The company reaffirmed its 2024 guidance of $160-165 million in total revenue and core adjusted earnings per diluted share of $5.50-5.70. Long-term projections indicate royalty receipts growing at a 22% compound annual growth rate, reaching approximately $285 million by 2029.
Over the past two years, Ligand has deployed $192 million across eight investments and is currently evaluating over $1 billion in actionable opportunities.
Ligand Pharmaceuticals (Nasdaq: LGND) has announced its participation in the Stifel 2024 Healthcare Conference in New York. CEO Todd Davis and CFO Tavo Espinoza will deliver a presentation on Tuesday, November 19, 2024, at 12:40 p.m. Eastern Time. The company's management team will also be available for one-on-one meetings with investors and conference attendees. Interested investors should contact their Stifel representative to schedule meetings.
Ligand Pharmaceuticals (Nasdaq: LGND) has announced plans to host an Investor and Analyst Day in Boston on December 10, 2024, from 10:30 a.m. to 12:00 p.m. Eastern Time. The event will feature presentations from senior management covering company strategy, investment activities, royalty portfolio, and long-term financial outlook. Key features include an in-person format, a live Q&A session, and accessibility via webcast through Ligand's Investor Relations website. A replay will be available after the event.
Ligand Pharmaceuticals (Nasdaq: LGND) has announced it will release its third quarter 2024 financial results before U.S. markets open on Thursday, November 7, 2024. The company will host a conference call at 8:30 a.m. ET (5:30 a.m. PT) the same day to discuss results and provide a business update. The call will be accessible via phone and webcast, with both live and replay options available.
Ligand Pharmaceuticals (Nasdaq: LGND) announced that its partner Travere Therapeutics received full FDA approval for FILSPARI® (sparsentan) to slow kidney function decline in adults with primary IgA nephropathy (IgAN) at risk of progression. This approval is based on positive long-term results from the PROTECT Study, showing FILSPARI significantly slowed kidney function decline over two years compared to irbesartan.
Key points:
- FILSPARI is the only non-immunosuppressive treatment for IgAN
- Ligand is entitled to a 9% royalty on worldwide net sales of FILSPARI
- FILSPARI demonstrated superior long-term kidney function preservation compared to irbesartan
- The FDA-approved label includes two-year efficacy data
Ligand's CEO, Todd Davis, expressed optimism about FILSPARI's potential as a significant revenue driver for the company in the coming years.
Ligand Pharmaceuticals (Nasdaq: LGND) announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference in New York. CEO Todd Davis and CFO Tavo Espinoza will present on Tuesday, September 10, 2024, at 8:30 a.m. Eastern Time.
The management team is also scheduled to host one-on-one meetings with investors and attendees during the conference. Interested investors should contact their H.C. Wainwright representative to arrange these meetings.
This event provides an opportunity for Ligand to showcase its business and engage with potential investors, potentially impacting the company's stock performance and investor relations.
FAQ
What is the current stock price of Ligand Pharma (LGND)?
What is the market cap of Ligand Pharma (LGND)?
